InSCREENex GmbH

Menu

Contact 🠇

-> Back to Products

CHO-Nav1.8

Nav1.8 CHO Stable Recombinant Cell Line

This Nav1.8 cell line is a recombinant clonal stable CHO cell line expressing full length human Sodium channel protein type 10 subunit alpha (SCN10A aka Nav1.8) plus beta subunit 1 (SCN1B). Electrophysiological characterization was performed by Metrion Biosciences. Detailed information and characterisation can be found in the Product Sheet.

Target Aliases

SCN10A, PN3, HPN3, SNS, Nav1.8

Cell Background

CHO-K1 (Chinese Hamster Ovary), epithelial-like cells, adherent but can be transferred into suspension.

  • Cells validated by

Buying and Ordering the Cells

For non-profit organizations, cells are available for perpetual academic research under the Limited Research Use License.

For-profit entities can purchase cells for perpetual commercial use under the Limited Commercial Use License.

To request a quote, please email us at or use the contact form provided below.

We are already registered on several digital order processing platforms, if you would like to add us as a registered supplier, please contact us at and we are happy to help.

Supplied as

Each license includes 1 vial of >2Mio viable cells. Additional or replacement vials can be purchased for a fee of 450€.

CHO - Phalloidin - DAPI
CHO - Phalloidin - DAPI
Representative current trace recorded from a CHO cell line stably expressing the Nav1.8 sodium channel. The black trace shows a slowly activating and inactivating inward sodium current in response to a depolarising voltage step from -100 mV to 0 mV. Scale bars indicate 100 pA and 2.5 ms for the current trace, with a voltage protocol schematic inset showing a 10 ms step to 0 mV from a -100 mV holding potential. The kinetics are consistent with Nav1.8’s characteristic slow inactivation profile.
Representative current trace for CHO-Nav1.8 (Cat.-No. INS-SF-1003). Data recorded on the QPatch (Sophion). Cell validation performed by Metrion Biosciences Ltd.
Activation curve for Nav1.8 sodium channels expressed in a stable CHO cell line. The plot shows normalised conductance (G/Gmax) on the y-axis as a function of membrane voltage (x-axis, from -60 mV to +20 mV). Data points, shown as black circles with error bars, depict a sigmoidal activation profile. The fitted curve indicates channel activation beginning near -30 mV, with half-maximal activation around -10 mV. An inset diagram illustrates the voltage protocol used, with depolarising steps from a holding potential of -80 mV to up to +15 mV in 100 ms intervals.
Activation curve for the CHO-Nav1.8 (Cat. No. INS-SF-1003) cell line. The half-maximal activation (V0.5) value of -11.3 mV is consistent with literature. Data recorded on the QPatch (Sophion). Cell validation performed by Metrion Biosciences Ltd.
Inactivation curve for Nav1.8 sodium channels expressed in a stable CHO cell line. The graph shows normalised current (I/Imax) on the y-axis plotted against membrane potential (x-axis, ranging from -100 mV to +20 mV). Black circles with error bars represent experimental data, and the fitted sigmoidal curve illustrates voltage-dependent inactivation. Peak currents are maintained at hyperpolarised potentials and progressively decline with depolarisation, with half-maximal inactivation occurring around -50 mV.
Inactivation curve for the CHO-Nav1.8 (Cat. No. INS-SF-1003) cell line. The half-maximal inactivation (V0.5) value of -49.4 mV is consistent with literature. Data recorded on the QPatch (Sophion). Cell validation performed by Metrion Biosciences Ltd.
Pharmacological characterisation of Nav1.8 sodium channels expressed in a stable CHO cell line, using two automated patch clamp platforms: qPatch (top row) and Qube (bottom row). Each panel shows dose-response curves for VX-150 prodrug (left) and PF04531083 (right), with inhibition data plotted against the logarithm of compound concentration. Black and purple data points represent inhibition measured after the first (P1) and second (P2) depolarisation pulses, respectively. Curves highlight use-dependent inhibition, with IC₅₀ values annotated in each graph. Inset voltage protocols depict P1 and P2 steps. Results show greater potency at P2 for both compounds, consistent with state-dependent block.
Pharmacological characterization for the CHO-Nav1.8 (Cat. No. INS-SF-1003) cell line. Data recorded on the QPatch (Sophion). Cell validation performed by Metrion Biosciences Ltd.
Cryovial
Cryovial
Cryovials
Cryovials
Catalog Number
INS-SF-1003
Features and Applications
  • Nav1.8 expression
  • CHO Background
  • Electrophysiological validation
Price Non-Profit (Academic Research)
Inquire
Price For-Profit (Commercial Use)
Inquire
Product Sheet
Download
Limited Research Use License
Download
Limited Commercial Use License
Download

Target Info

Background

Nav1.8 (SCN10A) is a voltage-gated sodium channel predominantly expressed in peripheral sensory neurons, playing a crucial role in nociception and pain signaling. Its selective expression and involvement in generating and propagating action potentials in nociceptors make it a validated therapeutic target for chronic pain conditions, including neuropathic and inflammatory pain. Dysfunctional Nav1.8 activity is implicated in multiple pain-associated disorders, underscoring its significance in pharmaceutical research. Notably, Nav1.8-specific inhibitors, such as suzetrigine (VX-548) developed by Vertex, have shown clinical promise in providing analgesia with improved tolerability profiles. Recombinant Nav1.8-expressing CHO cell lines facilitate the high-throughput screening and identification of selective modulators, accelerating drug discovery and optimization processes aimed at treating pain-related diseases.

Field of Research

  • Pain
  • Neuropathy
  • Non-opioid analgesics

Product Details

CHO - Low Density
CHO - Low Density
CHO - High Density
CHO - High Density

Stable recombinant CHO cells at low and high confluency, cultured in CHO Growth Medium A (INS-ME-1039) as a 2D monolayer.

Representative current trace recorded from a CHO cell line stably expressing the Nav1.8 sodium channel. The black trace shows a slowly activating and inactivating inward sodium current in response to a depolarising voltage step from -100 mV to 0 mV. Scale bars indicate 100 pA and 2.5 ms for the current trace, with a voltage protocol schematic inset showing a 10 ms step to 0 mV from a -100 mV holding potential. The kinetics are consistent with Nav1.8’s characteristic slow inactivation profile.
Representative current trace for CHO-Nav1.8 (Cat.-No. INS-SF-1003). Data recorded on the QPatch (Sophion). Cell validation performed by Metrion Biosciences Ltd.
Activation curve for Nav1.8 sodium channels expressed in a stable CHO cell line. The plot shows normalised conductance (G/Gmax) on the y-axis as a function of membrane voltage (x-axis, from -60 mV to +20 mV). Data points, shown as black circles with error bars, depict a sigmoidal activation profile. The fitted curve indicates channel activation beginning near -30 mV, with half-maximal activation around -10 mV. An inset diagram illustrates the voltage protocol used, with depolarising steps from a holding potential of -80 mV to up to +15 mV in 100 ms intervals.
Activation curve for the CHO-Nav1.8 (Cat. No. INS-SF-1003) cell line. The half-maximal activation (V0.5) value of -11.3 mV is consistent with literature. Data recorded on the QPatch (Sophion). Cell validation performed by Metrion Biosciences Ltd.
Inactivation curve for Nav1.8 sodium channels expressed in a stable CHO cell line. The graph shows normalised current (I/Imax) on the y-axis plotted against membrane potential (x-axis, ranging from -100 mV to +20 mV). Black circles with error bars represent experimental data, and the fitted sigmoidal curve illustrates voltage-dependent inactivation. Peak currents are maintained at hyperpolarised potentials and progressively decline with depolarisation, with half-maximal inactivation occurring around -50 mV.
Inactivation curve for the CHO-Nav1.8 (Cat. No. INS-SF-1003) cell line. The half-maximal inactivation (V0.5) value of -49.4 mV is consistent with literature. Data recorded on the QPatch (Sophion). Cell validation performed by Metrion Biosciences Ltd.
Pharmacological characterisation of Nav1.8 sodium channels expressed in a stable CHO cell line, using two automated patch clamp platforms: qPatch (top row) and Qube (bottom row). Each panel shows dose-response curves for VX-150 prodrug (left) and PF04531083 (right), with inhibition data plotted against the logarithm of compound concentration. Black and purple data points represent inhibition measured after the first (P1) and second (P2) depolarisation pulses, respectively. Curves highlight use-dependent inhibition, with IC₅₀ values annotated in each graph. Inset voltage protocols depict P1 and P2 steps. Results show greater potency at P2 for both compounds, consistent with state-dependent block.
Pharmacological characterization for the CHO-Nav1.8 (Cat. No. INS-SF-1003) cell line. Data recorded on the QPatch (Sophion). Cell validation performed by Metrion Biosciences Ltd.

Extensive electrophysiological validation by Metrion Biosciences using manual patch clamp and the QPatch and Qube automated patch clamp platform. See the Product Sheet for more details. Data below recorded on the QPatch.

ParameterNav1.8 CHO Cell Line
Expressed SubunitsSCN10A (α) + SCN1B (β)
ExpressionConstitutive (CMV)
Patch Clamp PlatformsManual, QPatch, Qube
TTX ResistanceYes (validated in presence of TTX)
Peak Current Amplitude–0.87 nA
Activation V₀.₅11.3 mV
Inactivation V₀.₅49.4 mV (QPatch)
Seal Formation Success94%
Recording Success86%
Stability Over TimeDetectable through ≥65 passages
Reference Compounds IC₅₀ values
(resting/inactivated)		VX-150: 158 nM / >1 µM
PF-04531083: >3 µM / 355 nM

We recommend the following reagents for the cell culture of this cell line:

Growth Medium: CHO Growth Medium A (INS-ME-1039)

Freezing Medium: Cell Freezing Medium (INS-SU-1027)

Coating: not required

  • Product Sheet including all relevant protocols and instructions (PDF)
  • Material Safety Data Sheet (PDF)
  • Request CoA (Email)

Coming Soon!

Stay tuned for comprehensive protocols for this cell line, from routine cell cultures to assay manuals.

Coming Soon!

Coming Soon!

Related Products

🠆 Cell Freezing Medium

Medium for cryopreservation of immortalized and stable cells.

  • Cryopreservation Medium
  • Ready-to-use
  • 30ml
More details
and prices 🠆
🠆 CHO Growth Medium A

Ready-to use Medium for culture of CHO cells (Type-A).

  • CHO culture (Type-A)
  • Ready-to-use
  • 500ml
More details
and prices 🠆
🠆 CHO-Nav1.7

Nav1. 7 expressing CHO recombinant stable cell line.

  • Nav1.7 expression
  • CHO Background
  • Electrophysiological validation
More details
and prices 🠆

Product FAQ

What cell background is used for these models?

Both the Nav1.7 and Nav1.8 cell lines are based on a proprietary CHO-K1-derived landing pad cell line developed by inscreenex. This platform allows site-specific, single-copy integration and supports stable, high-level expression in both adherent and suspension formats.

Yes. The Nav1.7 and Nav1.8 cell lines were validated on the Sophion QPatch platform, and Nav1.8 was additionally tested on the Qube system. Both cell lines demonstrated high seal formation and recording success rates, confirming suitability for automated workflows.

Each cell line is accompanied by a comprehensive data package including:

  • Peak current amplitudes

  • Activation and inactivation V₀.₅ values

  • Pharmacological IC₅₀ values for reference compounds

  • Recording success rates on automated systems

All data were generated by Metrion Biosciences Ltd, a leading CRO in ion channel electrophysiology.

es. The Limited Commercial Use License (LCUL) permits CROs to use the cells:

  • Under contract with a licensed client, or

  • Through direct licensing to offer fee-for-service work to third parties

Yes. inscreenex offers:

  • Gain- and loss-of-function mutants for Nav1.7 and Nav1.8 (e.g., IEM, PEPD, CIP)

  • Species-specific orthologs (mouse, rat, dog, Cynomolgus monkey)

All custom models are built using the same CHO landing pad platform.

Each order includes:

  • Two cryopreserved vials of the selected cell line (additional vials available for a service fee)

  • Detailed protocols for thawing, freezing, culture (adherent and suspension)

  • Patch clamp solution compositions and voltage protocols

Yes, both Nav1.7 and Nav1.8 cell lines are in stock and usually ship within 1–2 business days.
Estimated shipping times:

  • EU: 1–2 business days

  • UK: 2–3 business days

  • USA: 3–4 business days

  • Rest of world: please contact us for estimated delivery timelines

The cell lines are BSL1.

Cells are available for commercial use under a Limited Commercial Use License (LCUL).

This license permits:

  • Use by for-profit entities for internal drug discovery and development

  • Use by CROs, either under contract with the licensee or via direct licensing

For any other commercial uses (resale, batch-release, manufacturing etc.) , please contact our Out-Licensing Team.

You can request a quote or place an order by emailing: . For licensing inquiries or non-standard use cases: .

The cells are available under a one-time access fee, with no royalties or ongoing costs. Pricing includes two vials and the full licensing and protocol package. A discounted introductory offer is available when both cell lines are purchased together.

Literature and Reference

No research papers published yet.

 

We love to hear about your research! Please let us know if you have published using our cells.